Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
2.
Cardiovasc Diabetol ; 23(1): 169, 2024 May 15.
Article in English | MEDLINE | ID: mdl-38750502

ABSTRACT

Diabetic heart disease (DHD) is a serious complication in patients with diabetes. Despite numerous studies on the pathogenic mechanisms and therapeutic targets of DHD, effective means of prevention and treatment are still lacking. The pathogenic mechanisms of DHD include cardiac inflammation, insulin resistance, myocardial fibrosis, and oxidative stress. Macrophages, the primary cells of the human innate immune system, contribute significantly to these pathological processes, playing an important role in human disease and health. Therefore, drugs targeting macrophages hold great promise for the treatment of DHD. In this review, we examine how macrophages contribute to the development of DHD and which drugs could potentially be used to target macrophages in the treatment of DHD.


Subject(s)
Diabetic Cardiomyopathies , Macrophages , Oxidative Stress , Signal Transduction , Humans , Macrophages/drug effects , Macrophages/immunology , Macrophages/metabolism , Diabetic Cardiomyopathies/immunology , Diabetic Cardiomyopathies/metabolism , Diabetic Cardiomyopathies/drug therapy , Diabetic Cardiomyopathies/etiology , Animals , Oxidative Stress/drug effects , Fibrosis , Anti-Inflammatory Agents/therapeutic use , Myocardium/pathology , Myocardium/metabolism , Myocardium/immunology , Insulin Resistance , Inflammation Mediators/metabolism , Molecular Targeted Therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...